
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p
On 6ix: 6ix.com/news/ocular-therapeutixtm-announces-positive-phase-2-paxtravatm-glaucoma-data-at-the
Watch Ocular Therapeutix's latest callOcular Therapeutix (NASDAQ:OCUL) Q1 2026 Earnings Call · Replay · May 5Read the transcript of Ocular Therapeutix (NASDAQ:OCUL) Q1 2026 Earnings Call
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p
Ocular Therapeutix, Inc. on 6ix
Follow Ocular Therapeutix into a list and get an email when it puts out news.
Follow Ocular Therapeutix